Johnson & Johnson (NYSE: JNJ) EVP granted major stock awards

Rhea-AI Filing Summary

Johnson & Johnson executive Jennifer L. Taubert reported multiple equity transactions tied to long-term incentive awards. On February 13, 2026, she acquired common stock through the vesting and conversion of 1,302 Restricted Share Units and 27,412 Performance Share Units. Shares totaling 409 and 13,547 were withheld at prices of $244.55 per share to cover related tax obligations.

On February 15, 2026, she received new grants of 54,869 employee stock options and 3,940 Restricted Share Units under the company’s Long-Term Incentive Plan, and additional RSUs vested into 1,594 and 1,847 common shares. To satisfy taxes on these vestings, 816 and 945 shares were withheld at $243.45 per share. After these transactions, she continued to hold a substantial number of Johnson & Johnson common shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taubert Jennifer L

(Last) (First) (Middle)

ONE JOHNSON & JOHNSON PLAZA

(Street)

NEW BRUNSWICK NJ 08933

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, WWC. Innovative Medicine

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		1,302	A	$0(1)	179,315.001	D
Common Stock	02/13/2026		F		409(2)	D	$244.55	178,906.001	D
Common Stock	02/13/2026		M		27,412	A	$0(3)	206,318.001	D
Common Stock	02/13/2026		F		13,547(4)	D	$244.55	192,771.001	D
Common Stock	02/15/2026		M		1,594	A	$0(5)	194,365.001	D
Common Stock	02/15/2026		F		816(2)	D	$243.45	193,549.001	D
Common Stock	02/15/2026		M		1,847	A	$0(6)	195,396.001	D
Common Stock	02/15/2026		F		945(2)	D	$243.45	194,451.001	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	02/13/2026		M			1,302	(1)	(1)	Common Stock	1,302	$0	0	D
Performance Share Units	(3)	02/13/2026		M			27,412	02/13/2026	(3)	Common Stock	27,412	$0	0	D
Restricted Share Units	(5)	02/15/2026		M			1,594	(5)	(5)	Common Stock	1,594	$0	1,594(7)	D
Restricted Share Units	(6)	02/15/2026		M			1,847	(6)	(6)	Common Stock	1,847	$0	3,692(7)	D
Employee Stock Options (Right to Buy)	$243.45	02/15/2026		A		54,869		(8)	02/15/2036	Common Stock	54,869	$0	54,869	D
Restricted Share Units	(9)	02/15/2026		A		3,940		(9)	(9)	Common Stock	3,940	$0	3,940(7)	D

Explanation of Responses:

1. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting.

2. Shares withheld for payment of taxes upon vesting of RSUs.

3. Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting.

4. Shares withheld for payment of taxes upon vesting of PSUs.

5. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting.

6. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

7. Each RSU represents a contingent right to receive one share of Company Common Stock.

8. Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.

9. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

Remarks:

	/s/ Joleen Morgan, as attorney-in-fact for Jennifer Taubert	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did JNJ executive Jennifer Taubert report?

Jennifer L. Taubert reported equity transactions from vesting and new grants. She received common shares from RSU and PSU conversions and had shares withheld to cover taxes, alongside new grants of stock options and Restricted Share Units under Johnson & Johnson’s Long-Term Incentive Plan.

How many Johnson & Johnson stock options were granted to Jennifer Taubert?

She was granted 54,869 employee stock options. These options were awarded under Johnson & Johnson’s Long-Term Incentive Plan and are scheduled to vest in three equal annual installments starting on the first anniversary of the February 15, 2026 grant date.

What Restricted Share Unit awards did Jennifer Taubert receive at JNJ?

She received 3,940 Restricted Share Units on February 15, 2026. These RSUs, along with earlier awards from 2023, 2024, and 2025, vest in three annual installments and convert into Johnson & Johnson common stock on a one-for-one basis upon vesting.

Why were some JNJ shares disposed of in Jennifer Taubert’s Form 4?

Shares were disposed of solely for tax withholding. Specifically, 409 and 13,547 shares on February 13, 2026, and 816 and 945 shares on February 15, 2026, were withheld at prices around $244–$243 per share to satisfy tax obligations upon vesting.

How did RSUs and PSUs affect Jennifer Taubert’s JNJ common stock holdings?

Vesting RSUs and PSUs converted into common stock, increasing her direct holdings. On February 13, 2026, 1,302 RSUs and 27,412 PSUs converted; on February 15, 2026, additional RSUs converted into 1,594 and 1,847 common shares, partly offset by tax-withholding share disposals.